Summary
This Eleventh Circuit opinion reviews the FDA's Marketing Denial Order denying Bidi Vapor LLC's premarket tobacco product application for its Bidi Classic electronic nicotine delivery system. Applying the arbitrary and capricious standard under the Administrative Procedure Act, the court upheld the FDA's decision, finding that the agency reasonably determined the product's high abuse liability rendered it inappropriate for public health protection. The court declined to address the FDA's alternative technical deficiencies, concluding the abuse liability ground was independently sufficient to sustain the denial.
Topics
Practice areas
Questions Presented
- Whether the FDA’s Marketing Denial Order was arbitrary, capricious, or otherwise contrary to law under the APA.
- Whether the FDA properly applied the Tobacco Control Act’s public‑health standard.
- Whether the FDA was required to conduct a second‑cycle toxicological review.
- Whether the FDA improperly imposed product‑testing standards without notice‑and‑comment rulemaking.
Holdings
- The Court affirmed the FDA’s denial, finding that the agency’s action was not arbitrary or capricious and satisfied the statutory public‑health requirement.
- An agency’s decision may be upheld if at least one of the multiple grounds is independently sufficient, even if the others are invalid.
Key quotations
“The ‘arbitrary-and-capricious standard requires that agency action be reasonable and reasonably explained.’” (at 9)
“When an agency relies on multiple grounds for its decision, some of which are invalid, we may nonetheless sustain the decision as long as one is valid and the agency would clearly have acted on that ground even if the other were unavailable.” (at 9)
Factual background
Bidi Vapor sought approval to market its Bidi Classic ENDS product. The FDA found the product had high abuse liability, an incomplete leachable‑contaminant study, and insufficient comparative HPHC data, and therefore denied the application. Bidi Vapor submitted additional information but did not cure the abuse‑liability deficiency.
Procedural history
Bidi Vapor filed a pre‑market tobacco product application in 2020. The FDA issued a deficiency letter, Bidi Vapor submitted supplemental data, and on Jan. 22, 2024 the FDA issued a Marketing Denial Order based on three deficiencies. Bidi Vapor appealed the order to the Eleventh Circuit.